SWP
TOVX icon

Stratos Wealth Partners’s Theriva Biologics TOVX Stock Holding History

Stratos Wealth Partners’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-40
Closed -$5K – 1300
2021
Q3 		$5K Hold
40
– – ﹤0.01% 1183
2021
Q2 		$6K Sell
40
-3
-7% -$430 ﹤0.01% 1188
2021
Q1 		$7K Buy
+43
New +$8.5K ﹤0.01% 1117

Other funds holding TOVX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Stratos Wealth Partners's TOVX Position: Q4 2021 in Review

Stratos Wealth Partners sold out of Theriva Biologics (TOVX) in Q4 2021, closing a stake of 40 shares — an estimated $5K sold.

Stratos Wealth Partners first reported a position in TOVX in Q1 2021 and held it in 3 quarters. The position peaked at $7K in Q1 2021. 33 funds tracked by Wall St. Rank hold TOVX as of Q4 2021.

  • Stratos Wealth Partners reported no remaining Theriva Biologics position as of Q4 2021 after selling out during the quarter.
  • Stratos Wealth Partners sold 40 Theriva Biologics shares in Q4 2021, an estimated $5K.
  • Stratos Wealth Partners first reported a position in Theriva Biologics in Q1 2021 and held it in 3 quarters.
  • Stratos Wealth Partners's Theriva Biologics position peaked at $7K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2021.

Based on Stratos Wealth Partners's 13F filing for Q4 2021, filed 14 Jan 2022.